VivoSeq
Ophthalmology

Age-Related Macular Degeneration (AMD)

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Age-related Macular Degeneration (AMD) is an early-stage landscape with 2 programs across 3 companies. The most active players are Regeneron, Eli Lilly, Perceive Biotherapeutics, Inc.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

2 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3P

Perceive Biotherapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Pozelimab

Regeneron

Cemdisiran

Regeneron

Approved
No programs

Analysis

Modality Breakdown

2programs
Monoclonal antibody150%
RNA therapy150%

Modality classified for 67% of 3 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Completed1 · 33%
Enrolling by invitation1 · 33%

Clinical Trials

Trial Activity

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Recruiting·Regeneron logoRegeneron·Phase 3·NCT06541704·975 enrolled
Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
Completed·UUniversity Hospital, Limoges·Preclinical·NCT03690505·118 enrolled
Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study
Enrolling by invitation·PPerceive Biotherapeutics, Inc.·N/A·NCT07660640·88 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)